Olivia Taylor
Review: Lost Lantern Single Distillery Series: Whiskey Del Bac “Desert Dessert”
Nose
Smoked mesquite | Cherry | Nectarine | Nutmeg | Clove
Palate
Apricot | Orange | Cantaloupe | Dried fig | Toasted pie crust | Mildly sweet
Finish
Heavy smoked mesquite | Barrel char | Leather | Dark chocolate | Lingering smoky aftertaste
Overall
Desert Dessert doesn’t quite live up to its name, but instead offers a nice contrast with a fruit forward palate and dominating mesquite smoke on its backend.
Lost Lantern is a purveyor of single barrels highlighting up-and-coming and established craft whiskey distilleries. With their Single Distillery Series, Lost Lantern is highlighting Whiskey Del Bac, a malt distillery located in Tucson, Arizona. We reviewed a number of their whiskeys and even selected a single barrel from the distillery that attests to their creative way of making whiskey. This style is likely what attracted Lost Lantern to them.
Desert Dessert isn’t quite as sweet forward as its name suggests, but thanks to its sauternes and Pineau Des Charentes finish, its palate (and a lot of the nose) is very fruit forward. Apricot, orange, and cantaloupe create a pleasant flavor combination that works nicely against the intruding smoke-dominated finish that soon comes. It’s this heavy-smoked mesquite that monopolizes the rest of the sip and it’s challenging to manage, yet gets better with each sip.
Desert Dessert is a 450 bottle release.
Classification: Single Malt Finished in Sauternes and Pineau Des Charentes Barrels
Company: Lost Lantern
Distillery: Whiskey Del Bac
Release Date: April 2023
Proof: 113.9
Age: 1 Year
Mashbill: 60% Unsmoked Malted Barley, 40% Mesquited Malted Barley
Color: Dark Bronze
MSRP: $100 (2023)
Neurotez Pharmaceuticals, Inc. (the Company) was previously the parent company of Neurotez, Inc. (NZEI), a privately owned biopharmaceutical company focused on developing treatments for neurodegenerative disorders, including Alzheimer’s disease. However, in May 2019, NZEI merged with PharmatrophiX, Inc. to form PharmatrophiX, Inc. (PTX), a new publicly traded company.
As a result of the merger, the Company’s focus has shifted to the development and commercialization of treatments for chronic pain and other non-neurodegenerative disorders. The Company is currently in the pre-clinical stage of drug development and does not have any approved products on the market.
The Company plans to continue collaborating with other pharmaceutical companies and academic institutions to advance its drug candidates, as well as seeking potential licensing and partnership opportunities. The Company’s ultimate goal is to bring safe and effective treatments to patients in need.
1. d4 d6 2. g3 c6 3. Bg2 d5 4. Nc3 Nf6 5. Bg5 Bf5 6. Bxf6 exf6 7. e4 dxe4 8. Nxe4 Bxe4 9. Bxe4 Bb4+ 10. c3 Be7 11. Ne2 O-O 12. O-O Re8 13. Qd3 g6 14. Rfe1 f5 15. Bf3 Bd6 16. Nf4 Nd7 17. Qd2 Nf6 18. Rxe8+ Qxe8 19. Re1 Qd7 20. c4 Re8 21. Rd1 b6 22. Qd3 c5 23. dxc5 Bxf4 24. Qxd7 Nxd7 25. Rxd7 Bc1 26. cxb6 axb6 27. b3 Ba3 28. Bd5 Rf8 29. Rb7 Bc5 30. b4 Kg7 31. Rxb6 Bxb6 32. c5 Bc7 33. Kg2 Rb8 34. f4 Rxb4 35. a3 Rb5 36. c6 Rxd5 37. Kf3 Rc5 38. Ke3 Rxc6 39. Kd4 Ra6 40. Kd5 Rxa3 41. Kc6 Ba5 42. Kd7 Be1 43. Kc6 Ra2 44. Kd5 Rxh2 45. Kc4 Bxg3 46. Kd3 Bxf4 47. Kc4 g5 48. Kd5 g4 49. Kd4 g3 50. Kd3 g2 51. Kc2 g1=Q+ 52. Kd3 Qg3+ 53. Kc4 Bh6 54. Kd5 Rh4 55. Kc6 f4 56. Kd7 Qg6 57. Ke8 f3 58. Kd7 f2 59. Kc7 f1=Q 60. Kd7 Qd1+ 61. Kc7 Qgc2+ 62. Kb7 Qdb1+ 63. Ka6 Ra4# 0-1